Age-related macular degeneration (AMD) was described for the first time in the 1840s and is
currently the leading cause of blindness for patients over 65 years in Western Countries …

Neovascular age-related macular degeneration (vAMD), characterized by the neo-
vascularization of the retro-foveolar choroid, leads to blindness within few years. This …

Age-related macular degeneration (AMD) is the most common cause of irreversible loss of
central vision in elderly subjects, affecting men and women equally. It is a degenerative …

Due to an increasing number of abused drugs dumped into the wastewater, more and more
drugs are detected in the water environment, which may affect the survival of aquatic …

Four tyrosine kinase inhibitors, alectinib, apatinib, lenvatinib and anlotinib, have been
shown to be effective in the treatment of clinical tumors, but their cardiac risks have also …

Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs,
with relatively low patient compliance and potential risks. Ongoing research explores …

Angiokinases, such as vascular endothelial-, fibroblast-and platelet-derived growth factor
receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti …

In age‐related macular degeneration (AMD), choroidal neovascularization (CNV), a major
pathologic feature of neovascular AMD (nAMD), affects 10% of patients, potentially causing …

Lenvatinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of resistant
differentiated thyroid cancer, advanced renal cell carcinoma, unresectable hepatocellular …

Age-related macular degeneration (AMD) is a progressive degenerative disease that leads
to visual impairment, predominantly affecting the elderly. Despite significant advancements …